Myovant Ready To File Relugolix For Prostate Cancer

 
• By Joseph Haas

Secondary endpoint assessing cardiovascular risk may offer important differentiation from AbbVie’s Lupron. Myovant accelerated the prostate cancer filing soon after slowing the planned relugolix submission for uterine fibroids.

Cancer cell division of two prostate cancer cells in the final stage of cell division (cytokinesis) cytoplasm divides. the cells are joined by several thin cytoplasmic bridges. They to form tumours
Myovant now is on pace for two FDA filings of relugolix in 2020

More from Clinical Trials

More from R&D